Patrick Boland, MD
The combination of cetuximab (Erbitux) and pembrolizumab (Keytruda) was found to be well tolerated in patients with RAS
wild-type metastatic colorectal cancer (mCRC), according to findings of a phase Ib/II study presented at the 2018 Gastrointestinal Cancers Symposium.
wild-type and have received at least 1 prior systemic therapy in the metastatic or unresectable disease setting, are naïve to anti-EGFR therapy, and have measurable disease per RECIST 1.1 criteria.
Boland PM, Hutson A, Maguire O, et al. A phase Ib/II study of cetuximab and pembrolizumab in RAS-wt mCRC. J Clin Oncol. 2018;36(suppl 4S; abstr 834).
... to read the full story